Published in Pharma Law Weekly, August 16th, 2005
According to a report from England, "Single-pill amlodipine besylate/atorvastatin calcium (Caduet, Pfizer Inc., NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidemia (DYS)."
M.R. Cowie of University College in London wrote, "The benefits of lowering blood pressure (BP) in patients with HTN and lowering cholesterol in patients with DYS are well known and well studied. However, worldwide, many patients with HTN have concomitant DYS, which places them at greater risk for cardiovascular disease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly